Evogene Ltd. has 12 Schedule 13D or 13G filings on record since 2026-05-15. 2 holders' latest filing reports 5% or more of ordinary shares, par value nis 0.20 per share. Each figure below is the holder's own, as filed, with the filing linked.
Stated intent
Intent stated in Item 4 L.I.A. Pure Capital Ltd.
On July 10, 2026, the Reporting Persons delivered a letter to the Issuer demanding that the Issuer convene a special general meeting of shareholders.From Item 4 of the SCHEDULE 13D filed 2026-07-10
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| L.I.A. Pure Capital Ltd. | 19.35% | 3,057,488 | SCHEDULE 13D/A, 2026-09-11 | 2026-09-08 |
| Recanati Leon | 8.6% | 1,354,836 | SCHEDULE 13D/A, 2026-09-11 | 2026-08-04 |
| Armistice Capital, LLC | 4.99% | 713,539 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
Purpose of Transaction (Item 4)
L.I.A. Pure Capital Ltd.
Item 4 of the Schedule 13D is hereby amended to add the following at the end thereof: On September 8, 2026, the Reporting Persons delivered a letter to the Issuer notifying the Issuer that they, acting individually or jointly, intend to commence a special tender offer pursuant to Section 328 of the Israeli Companies Law, 5759-1999, which, if consummated, would result in the Reporting Persons holding, in the aggregate, not less than 25% of the Issuer's outstanding voting rights. A copy of the letter is attached hereto as Exhibit 9 and is incorporated herein by reference.Item 4 of the SCHEDULE 13D/A filed 2026-09-11
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2026-05-15 | Armistice Capital, LLC | 9.99% | SCHEDULE 13G |
| 2026-07-10 | L.I.A. Pure Capital Ltd. intent stated | 12.61% | SCHEDULE 13D |
| 2026-07-20 | L.I.A. Pure Capital Ltd. | 16.81% | SCHEDULE 13D/A |
| 2026-07-27 | L.I.A. Pure Capital Ltd. | 17.41% | SCHEDULE 13D/A |
| 2026-08-07 | L.I.A. Pure Capital Ltd. | 15.98% | SCHEDULE 13D/A |
| 2026-08-11 | Recanati Leon | 5.7% | SCHEDULE 13D |
| 2026-08-13 | Recanati Leon | 8.6% | SCHEDULE 13D/A |
| 2026-08-13 | L.I.A. Pure Capital Ltd. | 19.35% | SCHEDULE 13D/A |
| 2026-08-14 | Armistice Capital, LLC | 4.99% | SCHEDULE 13G/A |
| 2026-08-28 | L.I.A. Pure Capital Ltd. | 19.35% | SCHEDULE 13D/A |
| 2026-09-11 | Recanati Leon | 8.6% | SCHEDULE 13D/A |
| 2026-09-11 | L.I.A. Pure Capital Ltd. | 19.35% | SCHEDULE 13D/A |
Tools for this story
Each opens in a new tab, filled in for Evogene Ltd.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.